Gyros and SCRUM Sign Distribution Agreement for the Japanese Market
News Feb 17, 2010
Gyros® AB, a provider of automated micro-immunoassays for the development of biotherapeutics, announces the signing of an exclusive distribution agreement with SCRUM, a major supplier to the Japanese life-science market.
Under the terms of the agreement, SCRUM will market, sell and fully support the Gyros product range, within the Japanese biopharmaceutical, contract research and contract manufacturing industries.
The Gyrolab® system from Gyros is increasingly being employed by biopharmaceutical companies, and their contracted service organizations, during drug development and clinical trials. The company’s success in Europe and the USA has encouraged its expansion into Asia-Pacific, where Japan is regarded as a major market, the company explains.
"We are very happy to have such an experienced and well-established organization as SCRUM representing our products in the Japanese market", commented Erik Wallden, CEO and President of Gyros.
"We believe that Japan represents a key market for us and that this agreement with SCRUM will lead to a significant expansion of our presence in the Asia-Pacific region.”
Chinese researchers have developed interfacially polymerized porous polymer particles for low- abundance glycopeptide separation. These polymer particles - with hydrophilic-hydrophobic heterostructured nanopores - can separate low-abundance glycopeptides from complex biological samples with high-abundance background molecules efficiently.